Patient-recruitment specialist Synexus has opened an administrative center in Wroclaw, Poland, designed to oversee its expansion throughout Eastern Europe.
Quintiles has kicked off a study to determine whether early genomic profiling of cancer patients can help inform physician decisions and match the right participant with the right study, a method the CRO said could speed up the development process of personalized drugs.
Swiss CRO Psi is amping up its presence in Italy, the latest expansion for a clinical trial outfit looking to meet demand around the globe.
PPD has acquired Pennsylvania's Acurian, folding the company's clinical trial patient enrollment and retention services into its expanding eClinical operation.
Site management specialist Cenduit has made its first acquisition, buying Patient Reminders and rolling out a service that allows sponsors to communicate directly with clinical trial subjects.
Fresh off a private equity cash infusion, Australian CRO Novotech is expanding into Hong Kong and the Philippines, part of its ongoing effort to tap clinical trial demand in Asia.
In its 9 years in operation, PatientsLikeMe has recruited more than 200,000 members, culling data on symptoms, treatments and responses from disease sufferers around the world. Now, in its first deal with a CRO, the company has paired up with inVentiv Health to help recruit for clinical trials.
Patient-recruitment specialist Synexus has won a place in Pfizer's stable of preferred providers, giving the company advance information about future clinical trials and a leg up on other outsourcers.
Global consulting firm InVentiv Health has struck a partnership with the social analytics startup Medikly, believing that young company's technology gives it an edge in assisting its clients with finding physicians to participate in clinical research.
As the top cancer researchers gather in Chicago, the world's largest CRO is weighing in on how best to steer the future of oncology drug development, arguing that picking the right patients and biomarkers in early stages can mean the difference between a blockbuster and a late-phase failure.